Moderna slides after slashing sales outlook for 2025

Moderna Cuts 2025 Sales Forecast By $1 Bln On Weak Vaccine …

2 weeks from now

Jan 13, 2025  · Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 …

reuters.com

Moderna Crashes 17% After Slashing 2024-25 Guidance

2 weeks from now

Jan 13, 2025  · Moderna also cut its 2025 outlook and now projects just $1.5 billion to $2.5 billion, well below its prior view for $2.5 billion to $3.5 billion. Moderna stock crashed 16.8%, closing …

investors.com

Moderna Shares Drop To Five-Year Low After Slashing Revenue, …

2 weeks from now

Jan 13, 2025  · Moderna, which makes the Spikevax RNA-based Covid-19 vaccine, said before the bell it now expects between $1.5 billion and $2.5 billion in revenue in 2025, down from a …

marketwatch.com

Moderna Shares Tumble On Slashed Sales Guidance

2 weeks from now

Jan 13, 2025  · The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines. ... Moderna shares tumble on slashed …

biopharmadive.com

Moderna Stock Plummets 17% On 2025 Sales Guidance Slash

2 weeks from now

Jan 14, 2025  · The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative. Moderna Stock …

zacks.com

Moderna Shares Slide As It Slashes Revenue Forecast

2 weeks from now

Jan 13, 2025  · Moderna shares slide as it slashes revenue forecast ... $34.85 08:55 05/02/25-7.04%-$2.64. Moderna slashed its 2025 revenue projection by $1bn on ... Most of the sales …

sharecast.com

Moderna Shares Sink After Vaccine Maker Slashes 2025 Revenue …

2 weeks from now

Jan 13, 2025  · In November, Moderna said it expects to report 2024 sales of $3 billion to $3.5 billion despite the business making less from its COVID vaccine than in the prior year.

investing.com

Moderna Slides After Slashing Sales Outlook For 2025 - MSN

2 weeks from now

Moderna (NASDAQ:MRNA) shares plunged 20% premarket on Monday after the biotech firm cut its revenue guidance for 2025 on slow demand for its Covid and RSV vaccines. The company …

msn.com

Moderna Stock Poised For Another Drop After Shaving Nearly $1 …

2 weeks from now

Jan 13, 2025  · Drug maker Moderna's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook by $1 billion.. The company reported …

ibtimes.com

Moderna Shares Sink After Vaccine Maker Slashes 2025 Revenue …

2 weeks from now

Jan 13, 2025  · Investing.com - Moderna (NASDAQ: MRNA) shares slumped by more than 17% in premarket US trading on Monday after the drugmaker slashed its revenue guidance for 2025. …

investing.com

Watch These Moderna Price Levels As Stock Plummets After …

2 weeks from now

Jan 14, 2025  · Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. Watch these …

investopedia.com

Moderna Slashes 2025 Sales Forecast, Shares Sink

2 weeks from now

Jan 13, 2025  · Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plunged almost 20% after the drugmaker pre-announced fiscal 2024 sales below expectations. The company expects sales …

proactiveinvestors.com

Moderna Surprises The Street By Predicting A Bigger-than …

2 weeks from now

Jan 13, 2025  · Moderna said it expects 2025 revenue to range between $1.5 billion and $2.5 billion after hitting as much as $3.1 billion last year. Analysts expect, on average, $2.92 billion …

turnto10.com

Moderna Provides Business And Pipeline Updates At 43rd Annual …

2 weeks from now

Jan 13, 2025  · Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) Updates 2025 expected revenue range to …

modernatx.com

Moderna Adjusts 2025 Revenue Outlook, Shares Fall - Investing.com

2 weeks from now

Jan 13, 2025  · Moderna adjusts 2025 revenue outlook, shares fall. Stock Markets. Published 01/13/2025, ... The biotechnology company now expects its 2025 sales to fall between $1.5 …

investing.com

Moderna CEO Confronts Challenges For RSV, COVID Businesses

2 weeks from now

Jan 7, 2025  · During the third quarter, Moderna’s Spikevax sales reached $1.8 billion, outperforming consensus expectations of $1.15 billion. But analysts were reluctant to call the …

fiercepharma.com

Moderna Posts Surprise Profit As Covid Vaccine Sales Impress, Cost …

2 weeks from now

Nov 7, 2024  · Shares of Moderna were flat Thursday. Moderna is slashing expenses, with a recently announced goal of achieving $1.1 billion in savings by 2027, as it tries to recover from …

nbcnewyork.com

Merck Shares Plunge As Company Pauses Gardasil ... - NBC4 …

2 weeks from now

4 days ago  · The pharmaceutical giant anticipates 2025 sales of $64.1 billion to $65.6 billion, lower than the $67.31 billion that analysts surveyed by LSEG had expected. ... The outlook …

nbcwashington.com

Merck Touts 20 New ‘blockbuster’ Drugs In Development With $50 …

2 weeks from now

3 days ago  · Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China.

fortune.com

Merck 2025 Sales Forecast Underwhelms As It Pauses Gardasil Sales …

2 weeks from now

4 days ago  · For 2025 Merck expects adjusted earnings to range between $8.88 and $9.03 per share on $64.1 billion to $65.6 billion in sales. The data firm FactSet says analysts had been …

apnews.com